ArticleBMC pulmonary medicine2025
Serum CYFRA21-1 as a novel biomarker for predicting progressive pulmonary fibrosis in non-IPF interstitial lung disease, a cohort study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProgressive pulmonary fibrosis (PPF) represents a challenging phenotype of interstitial lung disease (ILD), characterised by functional deterioration and radiological progression despite treatment. The identification of reliable biomarkers to predict PPF remains a critical unmet need in clinical practice. This study aimed to investigate the predictive value of serum cytokeratin 19 fragment (CYFRA21-1) for PPF in patients with non-idiopathic pulmonary fibrosis (non-IPF) ILD.
methodsA retrospective cohort of 203 patients with non-IPF ILD were enrolled between January 2020 and December 2021 and followed for a median of 19 months. Baseline serum CYFRA21-1 levels were measured, and progression to PPF was defined according to the 2022 ATS clinical guideline. Associations between CYFRA21-1 levels and PPF risk were analysed using Cox proportional hazards models, and the optimal cut-off value was determined by receiver operating characteristic curve analysis.
resultsDuring follow-up, 48 patients (23.6%) developed PPF. Baseline CYFRA21-1 levels were significantly higher in the PPF group than in the non-PPF group (5.54 [4.36, 8.44] vs. 3.73 [2.63, 5.21] ng/mL, P < 0.001). Following variable selection via Least Absolute Shrinkage and Selection Operator (LASSO) regression, CYFRA21-1 was identified as an independent predictor of PPF in the multivariate Cox model (hazard ratio [HR] = 1.085, 95% confidence interval: 1.018-1.156, P = 0.013). The optimal cut-off value for CYFRA21-1 was determined to be 5.12 ng/mL (area under the curve = 0.712). Patients stratified by this cut-off (high vs. low CYFRA21-1) demonstrated significant differences in baseline lung function and computed tomography severity scores. Moreover, the high CYFRA21-1 group was associated with a substantially increased risk of PPF progression (HR = 3.803, P < 0.001).
conclusionsElevated serum CYFRA21-1 levels independently predict the development of PPF in patients with non-IPF ILD. It is correlated with impaired pulmonary function and radiographic severity. CYFRA21-1 may serve as a valuable biomarker for early risk stratification, supporting the need for validation in prospective multicentre studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.